Generic Upneeq Availability - Drugs.com (2024)

Last updated on Mar 6, 2024.

Upneeq is a brand name of oxymetazoline ophthalmic, approved by the FDA in the following formulation(s):

UPNEEQ (oxymetazoline hydrochloride - solution/drops;ophthalmic)

Manufacturer: RVL PHARMS
Approval date: July 8, 2020
Strength(s): 0.1% ^[RLD]

Has a generic version of Upneeq been approved?

No. There is currently no therapeutically equivalent version of Upneeq available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Upneeq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions and methods for treating ocular disorders
Patent 10,799,481
Issued: October 13, 2020
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL PHARMACEUTICALS, INC.
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Patent expiration dates:
- December 16, 2039
  ✓
  Patent use: METHOD OF TREATING BLEPHAROPTOSIS
Oxymetazoline compositions
Patent 10,814,001
Issued: October 27, 2020
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Patent expiration dates:
- December 16, 2039
  ✓
  See Also
  Getting Your Patient Started With Upneeq - Upneeq Upneeq Prices, Coupons, Copay & Patient Assistance - Drugs.com Can This Eye Drop Make You Look Dramatically More Awake?How To Fix Droopy Eyelids, Circles and Sags
  Drug product
Oxymetazoline compositions
Patent 10,898,573
Issued: January 26, 2021
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Patent expiration dates:
- December 16, 2039
  ✓
  Drug product
Compositions and methods for non-surgical treatment of ptosis
Patent 10,912,765
Issued: February 9, 2021
Inventor(s): Silverberg Mark
Assignee(s): VOOM, LLC
Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Patent expiration dates:
- August 26, 2031
  ✓
  Patent use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for treating ocular disorders
Patent 10,940,138
Issued: March 9, 2021
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Patent expiration dates:
- December 16, 2039
  ✓
  Patent use: METHOD OF TREATING BLEPHAROPTOSIS
Oxymetazoline compositions
Patent 11,103,482
Issued: August 31, 2021
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
See Also
Upneeq Application and TreatmentInformation | Upneeq
Patent expiration dates:
- December 16, 2039
  ✓
  Drug product
Patent 11,311,515
Patent expiration dates:
- December 16, 2039
  ✓
  Drug product
Patent 11,324,722
Patent expiration dates:
- December 16, 2039
  ✓
  Patent use: METHOD OF TREATING BLEPHAROPTOSIS
Patent 11,541,036
Patent expiration dates:
- December 16, 2039
  ✓
  Drug product
Patent 11,701,343
Patent expiration dates:
- December 16, 2039
  ✓
  Patent use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for non-surgical treatment of ptosis
Patent 8,357,714
Issued: January 22, 2013
Inventor(s): Silverberg Mark
Assignee(s): Voom, LLC
Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Patent expiration dates:
- August 26, 2031
  ✓
  Patent use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for non-surgical treatment of Ptosis
Patent 9,867,808
Issued: January 16, 2018
Inventor(s): Silverberg Mark
Assignee(s): VOOM, LLC
Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Patent expiration dates:
- August 26, 2031
  ✓
  Patent use: METHOD OF TREATING BLEPHAROPTOSIS

More about Upneeq (oxymetazoline ophthalmic)

Check interactions
Compare alternatives
Reviews (16)
Side effects
Dosage information
FDA approval history
Breastfeeding
En español

Patient resources

Upneeq drug information
Upneeq (Advanced Reading)

Other brands

Visine L.R. Long Lasting Redness Relief, OcuClear

Professional resources

Upneeq prescribing information
Oxymetazoline (AHFS Monograph)

Other brands

Visine L.R. Long Lasting Redness Relief

Related treatment guides

Blepharoptosis

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circ*mstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circ*mstances.

Medical Disclaimer

Generic Upneeq Availability - Drugs.com (2024)

FAQs

Is there a generic version of Upneeq? ›

Specifically, Upneeq is approved by the Food and Drug Administration (FDA) to treat droopy eyelids in adults. It's not available in a generic version.

How much is Upneeq without insurance? ›

The cost for Upneeq ophthalmic solution 0.1% is around $229 for a supply of 30 solution, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

Can you get a sample of upneeq? ›

Welcome to the UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 1% E-Sampling Portal where you can request UPNEEQ samples at your convenience. The sample allocation is customized specifically to your patient treatment needs and is based on your UPNEEQ patient starts.

Discover More Details ›

Can I use expired upneeq? ›

Keep this medication in the original container. Throw away any unused medication after the expiration date.

Find Out More ›

Is Lumify the same as Upneeq? ›

For example, Upneeq is a prescription eye solution that treats droopy eyelids in adults. You'll need to visit an eye doctor, dermatologist, or other healthcare professional to get a prescription for Upneeq. Lumify treats minor eye redness.

Learn More Now ›

What over the counter eyedrops are good for droopy eyelids? ›

Upneeq (oxymetazoline) is an alpha-1 receptor agonist. It's an eye drop used to treat droopy eyelids (acquired blepharoptosis) in people ages 13 years and older. The typical dose of Upneeq (oxymetazoline) is one drop in the affect eye(s) once per day.

Keep Reading ›

Will Medicare pay for Upneeq? ›

In general, Medicare prescription drug plans (Part D) do not cover this drug. Be sure to contact your specific plan to verify coverage information.

Tell Me More ›

Do you have to use Upneeq forever? ›

Even though the results are not permanent, you can continue to use Upneeq indefinitely. If you have droopy eyelids and want younger-looking eyes without surgical intervention, a Upneeq before and after transformation may be right for you.

Can you use 2 drops of Upneeq? ›

You'll apply one drop of Upneeq to one or both eyes (as directed by your doctor) once daily. Be careful that the eyedrop container does not touch your eye. If you wear contact lenses, remove them before applying Upneeq. Then wait at least 15 minutes before reinserting them.

Tell Me More ›

What are the negative side effects of Upneeq? ›

What are the most common side effects of Upneeq?

Eye tearing, redness, or discomfort.
Dry eye.
Blurred vision.
Pain after applying the eye drops.
Eye irritation.
Headache.

May 9, 2024

Does insurance cover Upneeq? ›

Does Insurance Cover Upneeq? Upneeq isn't considered a medically necessary treatment when used for cosmetic reasons, so health insurance doesn't cover the cost of the prescription.

Oxymetazoline ophthalmic	Lumify (brimonidine)	Fluorometholone ophthalmic
Brand Names
Upneeq, Visine L.R. Long Lasting Redness Relief	Other brimonidine brands include: Alphagan P, Lumify Preservative Free, Qoliana	Eflone, Flarex, FML, FML Forte Liquifilm, FML Liquifilm, FML S.O.P.

Upneeq (oxymetazoline)	Oxymetazoline ophthalmic
Dosage Form(s) Available
Ophthalmic solution	N/A
Brand Names
Other oxymetazoline brands include: Visine L.R. Long Lasting Redness Relief	Upneeq, Visine L.R. Long Lasting Redness Relief